The COMBINE-INTERVENE trial is a randomized international investigator-initiated trial to investigate whether a PCI revascularization strategy based on combined FFR and OCT assessment is superior to a PCI revascularization strategy based on FFR-alone in patients with MVD with any presentation. The COMBINE-INTERVENE trial is the first in line trial that will test focal percutaneous stenting for vulnerable plaque lesions independently from ischemia.

The COMBINE-INTERVENE trial is designed to enroll 1222 patients worldwide. The first patient was enrolled on 16 March 2022 in Romania. The trial geography includes about 50-60 centers in Europe, Asia-Pacific and North America. Patients will be followed for 2 years.


The ULtrasound guided TRAnsfemoral access in COmplex Large bORe trial is an international multicenter RCT and will randomized patients with planned complex large bore PCI to either ultrasound guided or fluoroscopy guided transfemoral access.

The ULTRACOLOR trial is an international, multicenter, prospective, randomized clinical trial designed to enroll 542 patients in 10 centers in the Netherlands, Belgium and Germany.


The ULTRA-CTO study is a prospective multicentre investigator-initiated trial designed to enroll subjects with an indication for percutaneous coronary intervention (PCI) of chronic total occluded (CTO) coronary artery and who have at least one intermediate (angiographically 30-90%) stenosis in a non-CTO vessel or major side branch of the CTO vessel with a diameter of at least 2 mm.

200 subjects will be enrolled in 2 centers in the Netherlands.

Dutch rivaroxaban CCS registry

The Dutch rivaroxaban CCS registry is a study which investigates the impact in terms of effectiveness and safety of the combination treatment of rivaroxaban 2.5 mg twice daily with aspirin on clinical outcomes and practices in a real-life Dutch patient population that are at high risk of ischemic events.

The multi-center study designed to enroll 1000 subjects will be conducted in the Netherlands.


The RFR-CABG trial aims to compare RFR guided versus angiography guided CABG revascularization and to define the best cut-off value that predicts graft occlusion for RFR.

The RFR-CABG trial is an international prospective randomized multicenter superiority trial designed to enroll 500 patients in Belgium, Slovakia and Poland.


The Dutch Cangrelor Registry aims to investigate the efficacy and safety of cangrelor in the Netherlands.

The Dutch Cangrelor Registry is a multicenter non-interventional prospective registry aiming to include 250 patients in 8 centres in The Netherlands.


The ECTOPIA trial aims to compare the efficacy of AAD (flecainide/verapamil and sotalol) and catheter ablation in reducing VPB burden after 3 months in patients with frequent symptomatic idiopathic VPB/VT.

The ECTOPIA trial is a national, multicenter, prospective, randomized clinical trial designed to enroll 180 patients in up to 6 centers in The Netherlands.


The COLOR trial aims to investigate whether transradial PCI is associated with less access site related bleeding- and/or vascular complications as compared with transfemoral PCI for complex coronary lesions with large-bore 7 Fr guiding catheters.

The trial is an international, multicenter, prospective, randomized clinical trial designed to enroll 388 patients in up to 12 centers in Europe (The Netherlands, Belgium, Germany, United Kingdom and Switzerland).


DETECT AF aims to examine the feasibility of screening persons of ≥65 years old for AAF and to validate the smartphone connected MED as an AAF screening instrument for application in transmural care in the Netherlands.

The DETECT AF project is a national prospective study designed to enroll 4000 patients in The Netherlands.


The TCW trial aims to investigate whether FFR-guided PCI and TAVI strategy for treatment of MVD and AS will be non-inferior to CABG and SAVR for a composite primary endpoint of all-cause mortality, stroke, myocardial infarction, coronary or valve re-intervention and life-threatening or disabling bleeding at one year.

The trial is a prospective, randomized, controlled, open label, multicenter, international, non-inferiority trial designed to enrol 328 patients in up to 22 centers in Europe (The Netherlands, Belgium, Germany, Denmark, Hungary, Spain, Greece, Austria, Slovakia and Portugal).